Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-citrulline for Prevention of Acute Lung Injury in Pediatric Heart Surgery
NCT02891837Phase 3Completed
- Sponsor
- Asklepion Pharmaceuticals
- Start
- Aug 2016
- Primary completion
- Jun 2019
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in acute lung injury (ALI) comparing L-citrulline with Placebo (2 arms). Primary endpoint: Composite Variable Consisting of the Longer of Either Length of Time on Mechanical Ventilation or Length of Inotrope Use at 28 Days. Started Aug 2016; status: completed.
02
Drugs
citrulline
03
Conditions
acute lung injury (ALI)
Beyond the preview
Go deeper on NCT02891837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02891837.